PMGC Holdings AI Stock Analysis
Want to see ELAB full AI Analyst Report?
PMGC Holdings (ELAB) AI Stock Analysis
PMGC Holdings
(NASDAQ:ELAB)
The overall score of 38 reflects a highly speculative and distressed investment. The most significant factors are the company's extremely weak financial performance, characterized by massive losses and cash burn, and a deeply negative technical trend. A failed preclinical study for a key asset further compounds the risk, outweighing any positive strategic corporate developments.
PMGC Holdings (ELAB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 257.41K
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 3.45
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 33
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PMGC Holdings Business Overview & Revenue Model
Company Description
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical...
PMGC Holdings Financial Statement Overview
Summary
Financial health is critically weak. While TTM revenue grew over 100% to $2.58M, the company is deeply unprofitable with a $13.5M net loss and a collapsed 10.3% gross margin. Cash burn is severe, with free cash flow at -$9.0M, and a new $13.9M debt load creates a risky 0.83 debt-to-equity ratio. This is a highly distressed financial profile.
Income Statement
18Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.58M | 590.08K | 2.47M | 0 | 766.28K | 827 |
| Gross Profit | 265.76K | 74.81K | 1.80M | -554 | 447.31K | 739 |
| EBITDA | -11.95M | -7.27M | -3.27M | -1.13M | -1.79M | -781.98K |
| Net Income | -13.49M | -7.71M | -6.25M | -4.30M | -1.80M | -784.74K |
Balance Sheet | ||||||
| Total Assets | 36.56M | 12.87M | 8.99M | 5.19M | 1.89M | 666.25K |
| Cash, Cash Equivalents and Short-Term Investments | 18.79M | 5.40M | 3.98M | 3.33M | 1.15M | 411.86K |
| Total Debt | 13.92M | 2.64M | 0 | 210.49K | 283.22K | 0 |
| Total Liabilities | 19.83M | 5.03M | 2.33M | 1.36M | 760.87K | 215.62K |
| Stockholders Equity | 16.74M | 7.84M | 6.66M | 3.83M | 1.13M | 450.63K |
Cash Flow | ||||||
| Free Cash Flow | -8.99M | -6.38M | -5.50M | -4.57M | -1.62M | -693.42K |
| Operating Cash Flow | -8.21M | -5.93M | -5.49M | -4.56M | -1.59M | -660.93K |
| Investing Cash Flow | -8.92M | -2.77M | -610.56K | -11.19K | -32.03K | -32.48K |
| Financing Cash Flow | 29.58M | 10.12M | 6.76M | 6.74M | 2.36M | 1.09M |
PMGC Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAB, the sentiment is Negative. The current price of 1.59 is below the 20-day moving average (MA) of 2.26, below the 50-day MA of 3.33, and below the 200-day MA of 26.36, indicating a bearish trend. The MACD of -0.55 indicates Negative momentum. The RSI at 18.90 is Positive, neither overbought nor oversold. The STOCH value of 16.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELAB.
PMGC Holdings Risk Analysis
PMGC Holdings disclosed 79 risk factors in its most recent earnings report. PMGC Holdings reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksPMGC Holdings Peers Comparison
Overall Rating
INDP51Neutral
INM50Neutral
BDRX40Underperform
CNSP38Underperform- ELAB38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| INDP | 51Neutral | $493.00M | -0.45 | -302.75% | ― | ― | 81.43% |
| INM | 50Neutral | $6.70M | -0.50 | -303.50% | ― | -82.91% | 55.05% |
| BDRX | 40Underperform | $1.26M | -45.33 | -42.42% | ― | ― | 97.97% |
| CNSP | 38Underperform | $5.29M | -0.15 | -204.25% | ― | ― | 88.43% |
| ELAB | 38Underperform | $1.28M | 0.00 | -118.11% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ELAB | PMGC Holdings Inc. | 1.59 | -1270.41 | -99.88% | |
| BDRX | Biodexa Pharmaceuticals Plc | 2.38 | -216.82 | -98.91% | |
| INDP | Indaptus Therapeutics, Inc. | 3.15 | 0.64 | 25.50% | |
| INM | Inmed Pharmaceuticals Inc. | 15.61 | -1.44 | -8.45% | |
| CNSP | Cns Pharmaceuticals, Inc. | 3.62 | -3.28 | -47.54% |
PMGC Holdings Corporate Events
PMGC Reports Preliminary Results from EL-32 Obesity Study
NegativeOn November 5, 2026, PMGC announced completion of an eight-week preclinical study evaluating EL-32 alone and with semaglutide in obese mice. The study examined body weight, body composition, glucose regulation and insulin sensitivity, and produced pr...
PMGC Holdings Agrees to Subscribe for Secured Debentures
NeutralOn October 30, 2026, PMGC Holdings Inc. agreed to subscribe for US$1.845 million of secured, non-interest-bearing debentures issued by Nuclea Energy Canada Inc. The financing was part of Nuclea Canada’s up-to-US$9 million offering, with proceeds desi...
PMGC Holdings Updates Investor Deck, Highlights Defense Strategy
PositiveOn October 28, 2026, PMGC Holdings prepared an updated corporate slide deck and a separate maritime defense technology deck for use in investor and stakeholder presentations. The materials outline how the company is positioning its diversified portfo...
PMGC Secures Long-Term Royalty Cash Flow Agreement
PositiveOn September 18, 2026, PMGC Holdings Inc. and its wholly owned subsidiary NorthStrive Biosciences Inc. entered into an interest-bearing payment agreement with Longevity Health Holdings, securing royalty payments from the January 2025 sale of the Elev...
PMGC Holdings advances AI-driven cardiometabolic expansion program
PositiveOn August 27, 2026, NorthStrive Biosciences, a wholly owned subsidiary of PMGC Holdings, executed a First Amendment to its Development and License Agreement with Yuva Biosciences to formalize a three-phase Expansion Program for four AI-discovered sma...
PMGC Holdings Secures New Trademark License Agreement
PositiveOn August 27, 2026, PMGC Holdings entered a five-year trademark license agreement with NorthStrive Companies Inc., gaining limited, royalty-free rights to use the NorthStrive brand and related marks for a nominal fee, tightening control over branding...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026